Young human plasma-derived extracellular vesicles rescue and reactivate IL-1β and TNF-α treated chondrocytes

Rongjie Wu1, Yu Xie1, Yujie Peng1

  • 1Department of Orthopedics, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510000, PR China; Shantou University Medical College, Shantou, Guangdong Province, 515000, PR China.

PubMed

Insights

Extracellular vesicles (EVs) from young plasma activate aging chondrocytes, promoting cartilage repair in osteoarthritis. These young EVs (YEVs) offer a promising therapeutic strategy for early-stage osteoarthritis by enhancing cell function and survival.

Area of Science:

  • Biomedical Engineering
  • Regenerative Medicine
  • Cell Biology

Background:

  • Osteoarthritis (OA) is a widespread degenerative joint disease with limited effective treatments.
  • Extracellular vesicles (EVs) from young sources show potential in activating aged cells.
  • The efficacy of young EVs in addressing age-related cartilage degeneration in OA is not yet established.

Purpose of the Study:

  • To investigate the potential of extracellular vesicles (EVs) derived from young human plasma (YEVs) to treat osteoarthritis.
  • To compare the effects of YEVs and old human plasma-derived EVs (OEVs) on chondrocytes in vitro.
  • To assess the therapeutic benefits of YEVs in an in vitro model of osteoarthritis.

Main Methods:

  • In vitro evaluation of YEVs and OEVs on human chondrocytes.
  • Assessment of chondrocyte proliferation, migration, and apoptosis in an osteoarthritis model.
  • Investigation of YEV stability after lyophilization and storage.

Main Results:

  • YEVs significantly enhanced chondrocyte proliferation and migration compared to OEVs.
  • YEVs protected chondrocytes against apoptosis induced by inflammatory factors (IL-1β and TNF-α) in an OA model.
  • Lyophilized YEVs maintained their physical characteristics during storage.

Conclusions:

  • YEVs demonstrate significant therapeutic potential for activating chondrocytes and promoting cartilage regeneration.
  • YEVs show promise for treating early-stage osteoarthritis, even in inflammatory conditions.
  • The stability of lyophilized YEVs supports their potential for clinical application.